Measures of disease frequency and prevalence of drug therapy related problems on basis of prospective observational study in rural hospitalization patients in Nellore
Aim and objectives: The study is aimed to assess the frequency and prevalence of drug therapy related problems in patients after hospitalization in Jayabharath Hospital, Nellore. Specific objectives: To estimate the opportunities for pharmacist to provide pharmaceutical care. A probabilistic convenient sampling was done to estimate the frequency and prevalence of drug therapy related problems, patients those who are aged above 18 years of either sex were included. Pregnant patients, and those who are having a unwillingness to participate in study were excluded. Methodology: This cross sectional study was conducted between March 2022 to June 2022 on patients who discharged to home from Jayabharath Hospital, Nellore. Most of our study population were within the age group of 30 to 45years (33.33 %) followed by 60 to 75years (25.00 %).among the present study population most of them were married (83.3 %) and illiterates (62.5 %). Results and Discussion: Nearly 50 drugs are responsible for drug related problems in the present study among those Phenytoin was found to be leading drug in relation to development of drug therapy related problems, Where as Nifedipine was found to be least problem producing drug in present study population. Conclusion: Overall we found various kinds of drug therapy related problems, which implies there is a need of continuity of care even after discharge from the hospital.
2. American public health association Pharmaceutical Care Guidelines Advisory Committee,www.marketresearch.com/product/display.asp?productid=1327146& APhA
Board of Trustees, 1995.
3. The pharmaceutical market: Peru. Espicom Healthcare Intelligence. 2006. www.marketresearch.com/product/display.asp?productid=1327146& (accessed 2007).
4. FIP Statement of Policy on Collaborative Pharmacy Practice. Statements and guide lines of pharmaceutical care. 1995, 20-21.
5. Mikeal RL, Brown TR, Lazarus HL, et al., Quality of Pharmaceutical care in hospitals. American journal of hospital pharmacy. 1975; 32(5): 567-574.
6. Brodie DC. Drug Use Control: keystone to pharmaceutical service. Drug Intelligence and Clinical Pharmacy. 1967; 1(1):63-65.
7. Bond CA, Raehl CL, Franke T. Interrelationships among mortality rates, drug costs, total costs of care and length of stay in United States hospital, summary and recommendations for clinical pharmacy services and staffing. Pharmacotherapy 2001; 21(4):129-141.
8. Parthasarthi G, Ramesh M, Hansen KN, Nagavi BG. Clinical pharmacy in a South Indian teaching hospital. The annals of Pharmacotherapy 2002; 36(5): 927-932.
9. Geer MI, Mir JI, Koul PA. Inauguration of Pharmaceutical Care Clinic for patient safety and therapeutic efficacy for chronic diseases management, drug information and pharmacoeconomics. International journal of community pharmacy 2009; 2(3): 1-4.
10. Kannan G, Janardhan V, Rani V, et al.,Pharmaceutical care in the general medicine ward of a tertiary care hospital in South India. Journal of Pharmacy Res 2011; 4(5): 1467- 1469.
11. PCNE. The PCNE Classification V 5.01 2006 29 May 2006 [cited 20 Sep 2009]. Availablefrom:http://www.pcne.org/dokumenter/DRP/PCNE%20classification%20V5.01. pdf.
12. AbuRuz SM, Bulatova NR, Yousef AM. Validation of a comprehensive classification tool for treatment-related problems. Pharma world science journal. 2006; 28(4):222–232.
13. Westerlund LT, Almarsdottir AB, Melander A. Drug-related problems and pharmacy interventions in community practice. International journal of pharmacy. 1999; 7(11): 40– 50.
14. Rawlins MD, Thompson JW. Mechanisms of adverse drug reactions In: Davies DM, editor. Textbook of adverse drug reactions. Oxford University Press, 1991: 18-45.
15. Inman WHW, editor. Monitoring for drug safety. 2nd ed. Lancaster: MTP Press, 1986.www.who .com www.who-umc.org/graphics/25257.pdf
16. Royer RJ. Mechanism of action of adverse drug reactions: an overview Pharma epidemiology Drug Saftey 1997; 3: 43-S50
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.